Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

New Test Detects All Viruses That Infect People, Animals

September 30, 2015 10:30 am | by Washington University in St. Louis | News | Comments

A new test detects virtually any virus that infects people and animals, according to research at Washington University School of Medicine in St. Louis, where the technology was developed. Read more...


New Data Shows Ofev Efficacy Sustained Long-Term in Patients With IPF

September 30, 2015 10:25 am | News | Comments

An interim analysis of the Inpulsis-ON open-label extension trial of Ofev (nintedanib) shows efficacy and safety that is consistent to that in the two identically-designed Phase 3 Inpulsis trials in patients with idiopathic pulmonary fibrosis (IPF). The results show no relevant changes in the safety and tolerability of Ofev. Read more...


Inroads Against Leukemia

September 30, 2015 9:37 am | by Harvard University | News | Comments

A molecule isolated from sea sponges and later synthesized in the lab can halt the growth of cancerous cells and could open the door to a new treatment for leukemia, according to a team of Harvard researchers and other collaborators led by Matthew Shair, a professor of chemistry and chemical biology. Read more...


How Technology is Transforming Personalized Medicine

September 30, 2015 9:17 am | by Troy Moore, chief scientific officer of Kailos Genetics | Articles | Comments

These are exciting times. Every day science and technology advancements offer new insights into the mechanics of human genetics. Maybe more importantly, the space is also rapidly evolving ways to use that information to deliver personalized medicine. Over the next decade, scientists likely will focus on deeply sequencing parts of the genome that prove to have a high degree of clinical utility. Read more...


Researchers Disguise Drugs as Platelets to Target Cancer

September 30, 2015 9:13 am | by North Carolina State University | News | Comments

Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient's own platelets, allowing the drugs to last longer in the body and attack both primary cancer tumors and the circulating tumor cells that can cause a cancer to metastasize. The work was tested successfully in an animal model. Read more...


Best Data Yet Show Fewer Seniors Get Flu When Others Vaccinate

September 30, 2015 9:06 am | by Cynthia Fox, Science Editor | Articles | Comments

The elderly are 21 percent less likely to get the flu if younger neighbors (aged 18 to 64) are vaccinated, according to a large and well-designed observational study. Read more...


Aspirin Lengthens Lives of Patients With Cancers in Digestive Tract

September 30, 2015 8:24 am | by Seth Augenstein, Digital Reporter | News | Comments

Daily aspirin use kept patients with cancers in the gastrointestinal tract alive longer, according to new research by a team of Dutch doctors. Read more...


Stem Cell Trial Aims to Cure Age-Related Macular Degeneration

September 30, 2015 8:24 am | by Stephanie Guzowski, Editor | News | Comments

London surgeons carried out a pioneering stem cell treatment in an ongoing trial for age-related macular degeneration (AMD). On Tuesday, a 60-year-old woman became the first person in the U.K. to receive the operation to cure the most common form of blindness. Read more...


Teva Gains Japanese Approval for Copaxone

September 30, 2015 7:55 am | News | Comments

The drug is intended for the prevention of relapse of multiple sclerosis. Read more...

HIV Patients Should be Included in Early Clinical Trials of Anti-TB Drugs

September 30, 2015 7:40 am | by European Lung Foundation | News | Comments

These findings were presented at European Respiratory Society’s International Congress 2015. Read more...


FDA Accepts Sanofi's NDA for Lixisenatide

September 30, 2015 7:30 am | News | Comments

The proprietary name for lixisenatide in the United States is under consideration. Read more...


Novel Oral Anticoagulants Require Improved Safety Data to Challenge Warfarin

September 30, 2015 7:20 am | by Lakshmi Dharmarajan, Ph.D, Senior Cardiovascular and Metabolic Disorders Analyst, GlobalData | News | Comments

Smaller observational studies and registry data should be exploited to obtain clinical evidence regarding the detrimental effects of lower doses of NOACs. Read more...


New Head-to-Head Stiolto Respimat Data Presented at ERS Annual Congress

September 29, 2015 12:32 pm | News | Comments

Boehringer Ingelheim Pharmaceuticals, Inc. today announced new data that show increase in FEV1 AUC0–12, which is a measure of lung function, with Stiolto Respimat compared to a European formulation of a combination of long-acting beta agonist (LABA), salmeterol, and inhaled corticosteroid (ICS), fluticasone propionate (50/500 µg, 50/250 µg). Read more...


Discovery Provides Insight into Life-Threatening Respiratory Distress in Newborns

September 29, 2015 12:21 pm | News | Comments

St. Jude Children's Research Hospital scientists have a lead on reducing life-threatening respiratory problems in infants born to women who develop the liver disorder intrahepatic cholestasis of pregnancy (ICP). The research appears today in the scientific journal Nature Communications. Read more...


Lilly's Cyramza Improves Progression-Free Survival in Bladder Cancer Trial

September 29, 2015 11:50 am | News | Comments

A Phase 2 study of Eli Lilly and Company's Cyramza (ramucirumab) in combination with docetaxel met its primary endpoint, demonstrating a statistically significant increase in progression-free survival (PFS) for patients with locally advanced or metastatic urothelial carcinoma who failed prior platinum-based therapy. Bladder cancer accounts for the vast majority of all urothelial carcinoma. Read more...



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.